Armata Pharmaceuticals VP Richard Rychlik Departs with Benefits
PremiumCompany AnnouncementsArmata Pharmaceuticals VP Richard Rychlik Departs with Benefits
1M ago
Armata Pharmaceuticals Updates Progress and Corporate Presentation
Premium
Company Announcements
Armata Pharmaceuticals Updates Progress and Corporate Presentation
3M ago
Armata Pharmaceuticals Welcomes David House as New SVP of Finance
Premium
Company Announcements
Armata Pharmaceuticals Welcomes David House as New SVP of Finance
3M ago
Armata Pharmaceuticals Updates Chief Medical Officer’s Compensation
PremiumCompany AnnouncementsArmata Pharmaceuticals Updates Chief Medical Officer’s Compensation
4M ago
Armata Pharmaceuticals completes enrollment of Phase 2 study of AP-PA02
Premium
The Fly
Armata Pharmaceuticals completes enrollment of Phase 2 study of AP-PA02
4M ago
Armata Pharmaceuticals Under Pressure: Navigating the Risks as Cost-Cutting Measures Threaten Revenue
Premium
Company Announcements
Armata Pharmaceuticals Under Pressure: Navigating the Risks as Cost-Cutting Measures Threaten Revenue
8M ago
Armata Pharmaceuticals: First patient dosed in Phase 2a portion of AP-SA02 study
PremiumThe FlyArmata Pharmaceuticals: First patient dosed in Phase 2a portion of AP-SA02 study
1y ago
Armata Pharmaceuticals reports Q2 EPS (17c) vs. (26c) last year
Premium
The Fly
Armata Pharmaceuticals reports Q2 EPS (17c) vs. (26c) last year
1y ago
ARMP Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ARMP Upcoming Earnings Report: What to Expect?
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100